Research highlighted by The Telegraph (14 July 2026) reports encouraging developments from the Alzheimer’s Association International Conference in London.
For many years, Alzheimer’s research has focused on slowing the progression of the disease after symptoms have already appeared. A major new international clinical trial aims to determine whether treatment can begin much earlier, before any memory problems develop and potentially prevent or significantly delay the onset of dementia.
The study will evaluate trontinemab, an investigational antibody therapy developed by Roche, in approximately 1,600 adults aged 55 to 80 who show biological markers associated with Alzheimer’s disease but who remain cognitively healthy.
A Shift Towards Prevention
Researchers increasingly recognise that the biological changes associated with Alzheimer’s begin many years before symptoms become apparent. Rather than waiting for memory loss or cognitive decline, the new trial seeks to identify individuals at increased risk using a simple blood test and intervene at this earlier stage.
Participants will be selected using blood measurements of p-tau217, a protein biomarker strongly associated with Alzheimer’s disease. Recent research suggests that elevated levels of this marker can identify individuals at substantially higher risk of developing cognitive impairment during the following decade.
If successful, this preventative approach has prompted some researchers to compare future Alzheimer’s treatment with the routine use of statins to reduce cardiovascular risk, protecting the brain before irreversible damage occurs.
Why Trontinemab Is Different
Trontinemab belongs to the same family of medicines as lecanemab and donanemab, the first drugs shown to modestly slow cognitive decline in people with early Alzheimer’s disease.
However, trontinemab has been engineered to cross the blood-brain barrier more efficiently. Early studies indicate that it removes amyloid plaques, the abnormal protein deposits associated with Alzheimer’s disease, more rapidly than earlier treatments while potentially causing fewer side effects.
Researchers reported that participants receiving the highest doses experienced almost complete removal of detectable amyloid plaques after only three monthly infusions, with maintenance treatment every three months appearing sufficient to keep plaque levels low.
Importantly, the current research has not yet demonstrated that this rapid plaque removal will translate into preventing or delaying dementia. That is precisely the question the new Phase III prevention trial is designed to answer.
Earlier Diagnosis Through Blood Testing
Another significant development presented at the conference concerns blood-based diagnosis.
Traditionally, confirming Alzheimer’s pathology has required expensive PET brain scans or invasive lumbar punctures. Blood testing for p-tau217 offers a much simpler alternative that could eventually become part of routine clinical practice.
Large studies presented alongside the trial suggest these blood tests can identify individuals at increased risk with a high degree of accuracy, potentially allowing clinicians to monitor patients much earlier in the disease process.
This represents one of the most promising advances in Alzheimer’s diagnosis for many years.
What This Could Mean
While trontinemab remains an investigational treatment and further evidence is needed before it could become widely available, the research signals an important change in the direction of Alzheimer’s medicine.
Instead of treating established dementia, scientists are increasingly focusing on preventing the disease before symptoms develop. If the ongoing trial confirms clinical benefit, it could fundamentally change how Alzheimer’s disease is detected and managed.
Although previous anti-amyloid therapies have demonstrated modest benefits, they have also been associated with significant monitoring requirements and potential complications, including brain swelling and bleeding. Early evidence suggests trontinemab may reduce these risks, although larger studies will be required to confirm its safety profile.
Looking Ahead
The results of the PrevenTRON Phase III trial are expected over the coming years. Success would represent a major milestone in dementia research and could pave the way for routine screening of people at increased risk, followed by preventative treatment before memory loss begins.
For researchers, clinicians, patients and families alike, this marks another encouraging step towards earlier diagnosis, more effective intervention and, ultimately, the possibility of preventing Alzheimer’s disease rather than simply slowing its progression.
Source acknowledgement: This article was inspired by reporting published in The Telegraph on 14 July 2026 by Health Editor Laura Donnelly. The underlying research was presented at the Alzheimer’s Association International Conference (AAIC 2026) and includes studies published in the Journal of the American Medical Association (JAMA).
